Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma.
Fiche publication
Date publication
octobre 2018
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Sharpnack MF, Ranbaduge N, Srivastava A, Cerciello F, Codreanu SG, Liebler DC, Mascaux C, Miles WO, Morris R, McDermott JE, Sharpnack JL, Amann J, Maher CA, Machiraju R, Wysocki VH, Govindan R, Mallick P, Coombes KR, Huang K, Carbone DP
Lien Pubmed
Résumé
Despite apparently complete surgical resection, approximately half of resected early-stage lung cancer patients relapse and die of their disease. Adjuvant chemotherapy reduces this risk by only 5% to 8%. Thus, there is a need for better identifying who benefits from adjuvant therapy, the drivers of relapse, and novel targets in this setting.
Mots clés
Biomarkers, Lung adenocarcinoma, NSCLC, Proteogenomics, Proteomics
Référence
J Thorac Oncol. 2018 10;13(10):1519-1529